Comparative Pharmacology
Head-to-head clinical analysis: CHLORPROPAMIDE versus LOGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORPROPAMIDE versus LOGEN.
CHLORPROPAMIDE vs LOGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stimulates insulin release from pancreatic beta cells by blocking ATP-sensitive potassium channels, increasing intracellular calcium, and enhancing peripheral insulin sensitivity. Also reduces hepatic glucose production.
LOGEN (lofepramine) is a tricyclic antidepressant that primarily inhibits the reuptake of norepinephrine and, to a lesser extent, serotonin at the presynaptic nerve terminal, increasing their concentrations in the synaptic cleft. It also has anticholinergic, antihistaminic, and alpha1-adrenergic blocking properties.
Initial: 250 mg orally once daily. Maintenance: 100-500 mg orally once daily.
1-2 tablets (5-10 mg loperamide) orally after first loose stool, then 1 tablet (5 mg) after each subsequent loose stool; maximum 8 tablets (40 mg) per day for acute diarrhea; 4-8 tablets (20-40 mg) daily in divided doses for chronic diarrhea.
None Documented
None Documented
Clinical Note
moderateChlorpropamide + Gatifloxacin
"Chlorpropamide may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateChlorpropamide + Rosoxacin
"Chlorpropamide may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateChlorpropamide + Levofloxacin
"Chlorpropamide may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateChlorpropamide + Trovafloxacin
36 hours (range 25-60 hours). Prolonged in renal impairment due to cumulative effects and hypoglycemia risk.
Terminal half-life is 2-4 hours in adults with normal renal function; extends to 8-12 hours in renal impairment. Clinical context: requires frequent dosing or renal dose adjustment.
Renal excretion of unchanged drug (80-90%) and hepatic metabolites (10-20%). Biliary/fecal excretion is minimal (<5%).
Renal excretion dominates: 70-80% of the dose is eliminated unchanged in urine; biliary/fecal excretion accounts for 10-15%. Minimal hepatic metabolism.
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic
"Chlorpropamide may increase the hypoglycemic activities of Trovafloxacin."